Peters Björn, Nasic Salmir, Jensen Gert, Stegmayr Bernd
Department of Nephrology, Skaraborg Hospital, Skövde, Sweden.
Department of Public Health and Clinical Medicine, Umeå University, Sweden.
Acta Radiol. 2020 Dec;61(12):1717-1723. doi: 10.1177/0284185120910590. Epub 2020 Mar 25.
Renal transplant biopsies are essential in nephrology; however, they are invasive and complications can occur.
To explore the risk of transplant kidney biopsy (TxB) complications in relation to possible preventive effects of desmopressin prophylaxis.
A total of 515 consecutive TxB (375 patients, median age 53 years) were analyzed. In 252 TxB, the Resistive Index (RI) was measured right before the biopsy. A total of 282 patients had serum creatinine >150 µmol/L. In one of the six hospitals 39/282 patients consecutively received desmopressin (dose 0.3 µg/kg subcutaneously) as prophylaxis within 1 h before the biopsy. Fisher's exact and χ test were used (odds ratio [OR], 95% confidence interval [CI]). Univariate and multiple binary logistic regression analyses were performed. A two-sided value <0.05 was considered significant.
RI ≥ 0.8 was a risk factor for major TxB complications (OR 4.2, 95% CI 1.13-15.76). The risk for minor complications decreased with mean arterial blood pressure (MAP) (97.9 vs. 89.5 mmHg, OR 0.97, 95% CI 0.95-0.997). In a multiple regression analysis for overall biopsy complications, the risk remained increased for patients with RI ≥ 0.8 (OR 4.45, 95% CI 1.32-15.04). No patients (0/39) with desmopressin prophylaxis had a major complication versus 8/243 in the other group. In patients with serum creatinine >150 µmol/L, those with a higher MAP had more overall TxB complications (104.5 vs. 98.2 mmHg, OR 1.05, 95% CI 1.004-1.1).
RI ≥ 0.8 was a risk factor for major and overall complications and a lower MAP for minor biopsy complications. Desmopressin prophylaxis showed yet no verified benefit as prophylaxis in TxB.
肾移植活检在肾脏病学中至关重要;然而,其具有侵入性且可能发生并发症。
探讨移植肾活检(TxB)并发症的风险以及去氨加压素预防的可能预防效果。
对总共515例连续的TxB(375例患者,中位年龄53岁)进行分析。在252例TxB中,活检前即刻测量阻力指数(RI)。共有282例患者血清肌酐>150 μmol/L。在六家医院中的一家,39/282例患者在活检前1小时内连续接受去氨加压素(剂量0.3 μg/kg皮下注射)作为预防措施。采用Fisher精确检验和χ检验(比值比[OR],95%置信区间[CI])。进行单因素和多因素二元逻辑回归分析。双侧P值<0.05被认为具有统计学意义。
RI≥0.8是TxB主要并发症的危险因素(OR 4.2,95% CI 1.13 - 15.76)。轻微并发症的风险随平均动脉压(MAP)降低(97.9对89.5 mmHg,OR 0.97,95% CI 0.95 - 0.997)。在总体活检并发症的多因素回归分析中,RI≥0.8的患者风险仍然增加(OR 4.45,95% CI 1.32 - 15.04)。接受去氨加压素预防的患者无主要并发症(0/39),而另一组为8/243。在血清肌酐>150 μmol/L的患者中,MAP较高者总体TxB并发症更多(104.5对98.2 mmHg,OR 1.05,95% CI 1.004 - 1.1)。
RI≥0.8是主要和总体并发症的危险因素,较低的MAP是轻微活检并发症的危险因素。去氨加压素预防在TxB中尚未显示出经证实的预防益处。